Home
Business
Metro
Nation
World
Sports
Feature
Opinion
View more »Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
Juvenile education requires input from all actors in society
Celebrating diversity in our food supply
Sunday
- Subscribe
Clinical trials completed
Print Edition
PHASE 1 clinical trials on a homegrown neutralizing antibody treatment for the novel coronavirus have been completed in Shanghai.
The new drug, JS016, was given to 40 healthy volunteers. The trials are the first of its kind to test neutralizing antibody treatment against the coronavirus in healthy people.
The trials showed the drug was safe and tolerable for human use.
JS016 is co-developed by Shanghai Junshi Biosciences and the Institute of Microbiology under the Chinese Academy of Sciences.
Clinical trials began at the Huashan Hospital on June 7, and led by Dr Zhang Jing and Dr Zhang Wenhong, who is also the leader of the expert team for coronavirus treatment in Shanghai.
The 40 volunteers were given the drug by July 7. To date, no side effects related to the doses have not been found.
Junshi said the company plans to start clinical trials on affected people as soon as possible.
Previous tests on monkeys showed JS016 can block the virus from entering cells, and decrease the virus in the lungs of affected monkeys.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
